State of Alaska Department of Revenue Sells 211 Shares of bluebird bio Inc (BLUE)

State of Alaska Department of Revenue reduced its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 3.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,174 shares of the biotechnology company’s stock after selling 211 shares during the quarter. State of Alaska Department of Revenue’s holdings in bluebird bio were worth $970,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Sphera Funds Management LTD. grew its stake in shares of bluebird bio by 77.0% in the fourth quarter. Sphera Funds Management LTD. now owns 138,796 shares of the biotechnology company’s stock worth $13,769,000 after purchasing an additional 60,400 shares during the last quarter. Advisor Group Inc. grew its stake in shares of bluebird bio by 15.5% in the fourth quarter. Advisor Group Inc. now owns 1,256 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 169 shares during the last quarter. Two Sigma Advisers LP bought a new stake in shares of bluebird bio in the fourth quarter worth about $4,385,000. California State Teachers Retirement System grew its stake in shares of bluebird bio by 1.3% in the fourth quarter. California State Teachers Retirement System now owns 85,930 shares of the biotechnology company’s stock worth $8,524,000 after purchasing an additional 1,065 shares during the last quarter. Finally, Retirement Systems of Alabama grew its stake in shares of bluebird bio by 22.1% in the fourth quarter. Retirement Systems of Alabama now owns 22,100 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 4,000 shares during the last quarter.

In other news, insider Kory James Wentworth sold 209 shares of bluebird bio stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $125.96, for a total transaction of $26,325.64. Following the completion of the transaction, the insider now directly owns 4,403 shares in the company, valued at $554,601.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey T. Walsh sold 1,500 shares of bluebird bio stock in a transaction that occurred on Friday, February 8th. The shares were sold at an average price of $131.29, for a total transaction of $196,935.00. Following the transaction, the insider now owns 42,421 shares of the company’s stock, valued at $5,569,453.09. The disclosure for this sale can be found here. Insiders sold 30,289 shares of company stock valued at $4,510,615 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

Several analysts recently issued reports on BLUE shares. Zacks Investment Research cut bluebird bio from a “hold” rating to a “sell” rating in a research note on Tuesday, January 8th. ValuEngine cut bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Cantor Fitzgerald set a $122.00 target price on bluebird bio and gave the stock a “hold” rating in a research note on Friday, March 22nd. Canaccord Genuity reissued a “buy” rating and issued a $161.00 target price (down from $250.00) on shares of bluebird bio in a research note on Wednesday, January 23rd. Finally, Oppenheimer reissued a “hold” rating on shares of bluebird bio in a research note on Friday, January 11th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $168.12.

Shares of BLUE opened at $137.06 on Friday. bluebird bio Inc has a one year low of $87.49 and a one year high of $199.70.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Thursday, February 21st. The biotechnology company reported ($2.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.83) by $0.11. bluebird bio had a negative net margin of 1,018.02% and a negative return on equity of 32.15%. The business had revenue of $19.20 million during the quarter, compared to analyst estimates of $9.06 million. During the same period last year, the business posted ($2.52) earnings per share. bluebird bio’s quarterly revenue was up 357.1% compared to the same quarter last year. As a group, analysts expect that bluebird bio Inc will post -11.62 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “State of Alaska Department of Revenue Sells 211 Shares of bluebird bio Inc (BLUE)” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/state-of-alaska-department-of-revenue-sells-211-shares-of-bluebird-bio-inc-blue.html.

bluebird bio Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Recommended Story: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.